atx101
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 3, 2025 (NCT06799845)
Timeline
Indications
Studied for
Mechanism of action
- Proliferating cell nuclear antigenINHIBITOR
PCNA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07107802 | Phase 1 | Jul 19, 2025 | Aurobac Therapeutics SAS |
| NCT06799845 | Phase 2 | Feb 3, 2025 | Allay Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allay Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Aurobac Therapeutics SAS | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1